25 completed, 9 terminated, 2 active not recruiting, 2 recruiting. 19 Phase 1, 16 Phase 2, 6 Not applicable, 1 Early Phase 1.
Follow T-Cell Large Granular Lymphocyte Leukemia: new trials by email Literature Review of T-Cell Large Granular Lymphocyte Leukemia trials Research Report on T-Cell Large Granular Lymphocyte Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia Ruxolitinib - T-Cell Large Granular Lymphocyte Leukemia | Phase 2 | Recruiting | Jonathan Brammer | 30 | 2023-05-03 | 2026-10-01 |
| Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia Oral Azacitidine - T-Cell Large Granular Lymphocyte Leukemia | Phase 1 / Phase 2 | Active not recruiting | Jonathan Brammer | 11 | 2022-06-29 | 2026-10-21 |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma Ruxolitinib, Duvelisib - T-cell Lymphomas, NK-Cell Lymphomas | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 70 | 2021-08-12 | 2026-09-09 |
| Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma carmustine, cytarabine, melphalan - Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma | Not applicable | Withdrawn | Fred Hutchinson Cancer Center | 2015-02-01 | 2015-05-07 | |
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 | Completed | Wake Forest University Health Sciences | 16 | 2014-09-01 | 2024-02-13 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Ipilimumab and Local Radiation for Selected Solid Tumors Ipilimumab, Radiation therapy - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Stanford University | 3 | 2013-02-01 | 2024-01-24 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2012-04-16 | 2018-04-11 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma plerixafor, filgrastim, etoposide - Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis | Not applicable | Terminated | Case Comprehensive Cancer Center | 25 | 2011-10-01 | 2019-06-14 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Fludarabine, Busulfan, Total Body Irradiation (TBI) - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 40 | 2011-08-04 | 2026-04-15 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Akt inhibitor MK2206, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2010-12-01 | 2020-11-04 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2010-11-24 | 2017-09-25 |
Showing 20 of 40. Sign in to see all of them.
Leukemia, Large Granular Lymphocytic (40) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (34) · Leukemia, Lymphocytic, Chronic, B-Cell (33) · Mycosis Fungoides (32) · Sezary Syndrome (32) · Lymphoma, Large-Cell, Anaplastic (31) · Lymphoma, T-Cell, Cutaneous (31) · Leukemia, Hairy Cell (30) · Lymphoma, Extranodal NK-T-Cell (29) · Burkitt Lymphoma (28) · Immunoblastic Lymphadenopathy (28) · Lymphoma, B-Cell, Marginal Zone (28) · Lymphoma, Follicular (28) · Waldenstrom Macroglobulinemia (28) · Lymphoma, Non-Hodgkin (27)
Hematologic Diseases (40) · Hemic and Lymphatic Diseases (40) · Immune System Diseases (40) · Immunoproliferative Disorders (40) · Leukemia, Lymphoid (40) · Leukemia, T-Cell (40) · Lymphatic Diseases (40) · Lymphoproliferative Disorders (40) · Neoplasms (40) · Neoplasms by Histologic Type (40) · Leukemia (39) · Disease Attributes (36) · Pathologic Processes (36) · Pathological Conditions, Signs and Symptoms (36) · Chronic Disease (33)
Peripheral Blood Stem Cell Transplantation (13) · Mycophenolic Acid (11) · Whole-Body Irradiation (10) · fludarabine phosphate (10) · Cyclosporine (8) · Cyclophosphamide (4) · Etoposide (4) · Busulfan (3) · Rituximab (3) · Tacrolimus (3) · Transplantation (3) · Azacitidine (2) · Cyclosporins (2) · Flow Cytometry (2) · Lenalidomide (2)
National Cancer Institute (NCI) (11) · Fred Hutchinson Cancer Center (10) · Case Comprehensive Cancer Center (3) · City of Hope Medical Center (2) · Jonathan Brammer (2) · Wake Forest University Health Sciences (2) · Children's Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · Morphotek (1) · Northwestern University (1) · Pierluigi Porcu (1) · Roswell Park Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Stanford University (1) · University of Chicago (1)
United States (40) · Italy (5) · Germany (3) · Canada (2) · Australia (1) · Denmark (1) · New Zealand (1) · Puerto Rico (1) · Switzerland (1)
Brenda Sandmaier (3) · Ann Woolfrey (2) · David Maloney (2) · Jonathan Brammer, MD (2) · Mohamed Sorror (2) · Ryotaro Nakamura (2) · Adam Petrich, MD (1) · Ajay Gopal (1) · Alison Moskowitz, MD (1) · Brenda Cooper, MD (1) · Brian Hill, MD (1) · David Hong (1) · George A. Fisher, MD, PhD (1) · George Chen (1) · Hongtao Liu (1)
PMID 32499241, PMID 18698002, PMID 19900571, PMID 22259028, PMID 24474568, PMID 26213141, PMID 26853648, PMID 29292843, PMID 30562587, PMID 31617432
P30CA015704 (10), P01CA018029 (5), N01CM62202 (2), P30CA016672 (2), P30CA043703 (2), U01CA062502 (2), U01CA062505 (2), U01CA097452 (2), N01CM00039 (1), P01CA044991 (1), P01CA078902 (1), P30CA012197 (1), P30CA016058 (1), P30CA021765 (1), P30CA033572 (1)